⁶⁸Ga-DPA in the Lung Cancer Diagnosis

NCT07023068 · tracked via the Priya Life Science China tracker

Sponsor

Peking Union Medical College Hospital

Phase

Phase EARLY_PHASE1

Started

2024-09-28

Last updated

2025-06-15

Condition(s) studied

Lung Cancers

Investigational drug(s) / intervention(s)

68Ga-DPA PET/CT

68Ga-DPA PET/CT: Use 68Ga-DPA PET/CT in the diagnosis of lung cancer

Study summary

In previous studies, we synthesized a PD-L1-targeted molecular probe, ⁶⁸Ga-DPA, and developed a ⁶⁸Ga-DPA injection for clinical research. Preliminary studies demonstrated its favorable safety profile and excellent imaging performance. Leveraging the established strengths of the Department of Nuclear Medicine at Peking Union Medical College Hospital, we now plan to conduct an exploratory PET/CT imaging study in lung cancer patients. This study aims to provide an in vivo, non-invasive, and visualizable technique for detecting PD-L1 expression levels and spatial distribution in tumors. It will further validate the clinical utility of this technology, offering critical diagnostic insights for initial assessment and treatment efficacy evaluation in PD-L1-positive tumor patients undergoing PD-L1-targeted therapies.

Eligibility

Sex

ALL

Min age

18 Years

Max age

85 Years

Healthy volunteers

Inclusion Criteria: * Age ≥18 years, regardless of gender. * Patients clinically confirmed or suspected of lung cancer, with pathological specimens obtainable via biopsy or surgery within the recent 2 months. * At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. * Expected survival \>3 months. Exclusion Criteria: * Severe hepatic or renal dysfunction (serum creatinine \>3.0 mg/dL or any liver enzyme level ≥5× upper limit of normal). * Women who are planning pregnancy, pregnant, or breastfeeding. * Inability to lie supine for 30 minutes. * Claustrophobia or other psychiatric disorders. * Intolerance to any clinical procedures in the study. * Other conditions deemed ineligible by the investigator.

Primary outcome measure(s)

SUV — 0-180 minutes post-injection
measured by PET/CT

Trial sites (1)

Facility	City	Region	Status
100730	Beijing	China

More Peking Union Medical College Hospital trials in China

68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC. Recruiting

A Prospective Cohort Study of Myasthenia Gravis in China Recruiting

68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma Starting soon

National Registry of IgG4-RD in China Recruiting

Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer Active, not recruiting

Other trials for the same condition

SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis Starting soon

A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery Recruiting

Assessment the Effectiveness of BTVA in COPD and Ablation in Pulmonary Nodules by Pulmonary MRI Recruiting

An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors Recruiting

AI-Assisted Non-Contrast CT for Multi-Cancer Screening Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07023068 on ClinicalTrials.gov ↗ ← All trials in China